Atlas Trials

Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients

Clinical trial NCT01543464 · TERMINATED

Trial details

NCT number
NCT01543464
Sponsor
Inge Marie Svane
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Malignant Melanoma
Start date
2012-05-01
Primary completion
2016-09-01
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.